credits bmbl December 7 '06.doc - Central Michigan University

More documents

Recommendations

Info

Occupational Health and Immunoprophylaxis 10. National Research Council (US), Committee on Occupational Health and Safety in the Care and Use of Nonhuman Primates, Institute for Laboratory Animal Research, Division on Earth and Life Studies. Occupational health and safety in the care and use of nonhuman primates. Washington, DC: National Academy Press; 2003. 11. Cohen JI, Davenport DS, Stewart JA, et al. Recommendations for prevention of and therapy for exposure to B virus (cercopithecine herpesvirus 1). Clin Infect Dis 2002;35:1191-203. 12. Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 2002;51:1-35. 13. Centers for Disease Control and Prevention. Update on adult immunization. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep. 1991;40:1-94. 14. Centers for Disease Control and Prevention. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep. 1997;46:1-42. 15. Centers for Disease Control and Prevention. Use of vaccines and immune globulins in persons with altered immunocompetence. Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1993 Apr 9;42(RR-04):1-18. 16. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996 Sep 6; 45(RR-12):1-35. Erratum in: MMWR Morb Mortal Wkly Rep. 1997;46:227. 17. United States Department of Health and Human Services [www.dhhs.gov]. Washington, DC: The Department; [updated 2006 Mar 6]. Office of Human Research Protections Guidance; [about two screens]. Available from: http://www.hhs.gov/ohrp/ 18. United States Food and Drug Administration [www.fda.gov]. Rockville, MD; The Administration; [updated 2005 June 13]. Information on Submitting an Investigational New Drug Application for a Biological Product [about3 screens]. Available from: http://www.fda.gov/cber/ind/ind.htm 19. Social Security Administration [www.ssa.gov]. Baltimore: The Administration; [updated on 2006 Jul 24]. Reports and Studies. Committee on Economic Security (CES); [about 22 screens]. Available from: http://www.ssa.gov/history/reports/ces/ces6kjaer.html 137
Page 1 and 2:
Biosafety in Microbiological and Bi
Page 3 and 4:
SECTION VIII-H: Prion Diseases 299
Page 5 and 6:
Forward Biosafety in Microbiologica
Page 7 and 8:
Editors: L. Casey Chosewood, MD Dir
Page 9 and 10:
Guest Editors: Matthew J. Arduino,
Page 11 and 12:
Charles B. Millard, PhD Lieutenant
Page 13 and 14:
Robert Bull Karen B. Byers Jane Cap
Page 15 and 16:
Thomas L. Miller Douglas M. Moore M
Page 17 and 18:
Robert Yarchoan Uri Yokel Lisa Youn
Page 19 and 20:
Introduction laboratories chose not
Page 21 and 22:
Introduction RISK CRITERIA FOR ESTA
Page 23 and 24:
Introduction BMBL includes an impor
Page 25 and 26:
Section II Biological Risk Assessme
Page 27 and 28:
Biological Risk Assessment informat
Page 29 and 30:
Biological Risk Assessment The NIH
Page 31 and 32:
Biological Risk Assessment effectiv
Page 33 and 34:
Biological Risk Assessment Third, m
Page 35 and 36:
Biological Risk Assessment 14. Oxma
Page 37 and 38:
Principles of Biosafety Safety equi
Page 39 and 40:
Principles of Biosafety Often an in
Page 41 and 42:
Principles of Biosafety Four standa
Page 43 and 44:
Principles of Biosafety 4. Centers
Page 45 and 46:
Laboratory Biosafety Level Criteria
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Section V Vertebrate Animal Biosafe
Page 77 and 78:
Vertebrate Animal Biosafety Level C
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86: Vertebrate Animal Biosafety Level C
Page 119 and 120: TABLE 1 SUMMARY OF RECOMMENDED BIOS
Page 121 and 122: Principles of Laboratory Biosecurit
Page 131 and 132: Occupational Health and Immunoproph
Page 134 and 135: Occupational Health and Immunoproph
Page 138 and 139: SECTION VIII Agent Summary Statemen
Page 140 and 141: Agent Summary Statements - Bacteria
Page 186 and 187:
Agent Summary Statements - Fungal A
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Agent Summary Statements - Parasiti
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Agent Summary Statements - Ricketts
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Agent Summary Statements - Viral Ag
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
• Section VIII-F: Arboviruses and
Page 246 and 247:
Agent Summary Statements - Arboviru
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Agent Summary Statements - Toxins f
Page 288 and 289:
Agent Summary Statements - Toxins D
Page 290 and 291:
Agent Summary Statements - Toxins (
Page 292 and 293:
Agent Summary Statements - Toxins r
Page 294 and 295:
Agent Summary Statements - Toxins e
Page 296 and 297:
Agent Summary Statements - Toxins 8
Page 298 and 299:
Agent Summary Statements - Toxins 4
Page 300 and 301:
Agent Summary Statement - Prion Dis
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Appendix A Primary Containment for
Page 308 and 309:
Appendix A HEPA Filters. Control of
Page 310 and 311:
Appendix A The Class II (Types A1,
Page 312 and 313:
Appendix A Type B1 cabinet, approxi
Page 314 and 315:
Appendix A Horizontal Laminar Flow
Page 316 and 317:
Appendix A and increase the possibi
Page 318 and 319:
Appendix A collection flasks should
Page 320 and 321:
Appendix A Small spills within the
Page 322 and 323:
Appendix A and skin from UV exposur
Page 324 and 325:
Appendix A Annex F of NSF/ANSI 49 2
Page 326 and 327:
Appendix A H. Vibration Test: This
Page 328 and 329:
Appendix A Table 2. Comparison of B
Page 330 and 331:
Appendix A Table 4. Reference for A
Page 332 and 333:
Appendix A Figure 2. The Class I BS
Page 334 and 335:
Appendix A Figure 4. Canopy (thimbl
Page 336 and 337:
Appendix A Figure 6. The Class II,
Page 338 and 339:
Appendix A Figure 9A. The horizonta
Page 340 and 341:
Appendix A Figure 10. A modified co
Page 342 and 343:
Appendix A Figure 13. A bag-in-bag-
Page 344 and 345:
Appendix A 17. Barbeito M, West, D,
Page 346 and 347:
Appendix B an item is either steril
Page 348 and 349:
Appendix B decontamination of equip
Page 350 and 351:
Appendix B minimum and are “sight
Page 352 and 353:
Appendix B TABLE 2 ACTIVITY LEVELS
Page 354 and 355:
Appendix B 8. Tearle P. Decontamina
Page 356 and 357:
Appendix C United States Postal Ser
Page 358 and 359:
Appendix C CDC Select Agent Program
Page 360 and 361:
Appendix C FIGURE 1 A CATEGORY A UN
Page 362 and 363:
Appendix C FIGURE 2 A CATEGORY B NO
Page 364 and 365:
Appendix D The BSL-3-Ag facility ca
Page 366 and 367:
Appendix D facility in the future.
Page 368 and 369:
Appendix D 1. Personnel change and
Page 370 and 371:
Appendix D acceptance of the facili
Page 372 and 373:
Appendix D V. SUMMARIES OF SELECTED
Page 374 and 375:
Appendix D means of transmitting th
Page 376 and 377:
Appendix D The primary natural mode
Page 378 and 379:
Appendix D movement permit is requi
Page 380 and 381:
Appendix D is probably because reco
Page 382 and 383:
Appendix D tick), A. cajennese, and
Page 384 and 385:
Appendix D LSD is a disorder of cat
Page 386 and 387:
Appendix D isolated from stillborn
Page 388 and 389:
Appendix D Peste Des Petits Ruminan
Page 390 and 391:
Appendix D movement permit is requi
Page 392 and 393:
Appendix D The importation, possess
Page 394 and 395:
Appendix D 21. DaMassa AJ, Holmberg
Page 396 and 397:
Appendix D 55. Kitching RP, Mackay
Page 398 and 399:
Appendix E Four Arthropod Containme
Page 400 and 401:
Appendix G Integrated Pest Manageme
Page 402 and 403:
Appendix G Preventive applications
Page 404 and 405:
Appendix H REFERENCES 1. Doblhoff-D
Page 406 and 407:
Each laboratory that uses toxins sh
Page 408 and 409:
disposable plastic pipettes. Glass
Page 410 and 411:
TABLE 1 PHYSICAL INACTIVATION OF SE
Page 412 and 413:
f For T-2 mycotoxin and brevetoxin,
Page 414 and 415:
23. Robinson JP. Annex 2. Toxins. I
Page 416 and 417:
Appendix J 4. Approval by the IBC p
Page 418 and 419:
Appendix K Atlanta, Georgia 30333 T
Page 420 and 421:
Appendix K USDA, Agriculture Select
Page 422 and 423:
Appendix L Acronyms ABSA ABSL ABSL-
Page 424:
Appendix L NIH Guidelines NIOSH OBA
show all

credits bmbl December 7 '06.doc - Central Michigan University

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?